Insights on AI-Driven Clinical Evidence
Expert perspectives on Real-World Evidence study design, EDC and eCRF implementation, AI-powered clinical data validation, CDISC/CDASH compliance, regulatory strategy, and lessons learned from 500+ delivered studies.
How AI Validation Engines Cut Phase 4 Post-Market Timelines by 45%
A deep dive into how RWEOne's AI-driven data validation and automated query generation reduced query resolution time and compressed post-market safety study timelines for a top-20 global pharma sponsor.
The Complete 2026 Guide to CDISC/CDASH-Compliant EDC and eCRF Design
Everything sponsors need to know about building electronic Case Report Forms that align with CDISC CDASH standards from day one — avoiding costly mid-study rework and regulatory submission delays.
From RWE Studies to RWD Lakes: Architecting Continuous Evidence
Why leading pharma sponsors are moving beyond one-off RWE studies and building long-term Real-World Data lakes that power lifecycle evidence, commercial analytics, and regulatory submissions.
RWE Feasibility in Ultra-Rare Diseases: A Site Network Playbook
Lessons learned from 40+ rare-disease studies: how to design feasible protocols, activate specialty investigator sites, and recruit patients for ultra-rare indications in record time.
Audit Trails Under 21 CFR Part 11 and GxP: What Sponsors Must Prove
A regulatory walkthrough of the audit trail requirements every clinical sponsor is expected to meet — and how event-driven RabbitMQ-based architectures deliver 100% audit readiness by design.
How Digital CTA Signatures Cut Site Activation Time by 40%
A quantitative analysis across 120 sites spanning 18 countries: the impact of fully-digital Clinical Trial Agreement signatures and investigator onboarding workflows on study start timelines.
Get Monthly RWE & Clinical AI Insights
A curated digest delivered once per month: new case studies, regulatory updates, technical guides, and platform releases — curated for clinical operations, medical affairs, and drug development leaders.